A lack of diversity in clinical trials means that most medicines are created specifically for middle income white men.  This is significant as “advances in genetics have taught us that gender, race, and socioeconomic status can change how medications work in our bodies.  For instance, one 2009 study found bisphenol-A (BPA) was more likely to cause preterm births among the poor than the rich, and a 1999 study found that black patients, but not white ones, may be protected from heart disease by a novel combination of existing drugs.”  With 40% of America being diverse, clinical testing is looking to increase their current numbers of only 5% and 1% black and Hispanic participation respectively.